| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Departments of Surgery [F. T., W. H., M. T. L., H. T.] and Molecular Genetics and Biochemistry [F. T., W. H., P. D. R., M. T. L., H. T.], University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, and Division of Host Defenses, Institution for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan [H. O.]
We hypothesized that antitumor-specific immunity, which is induced by
interleukin (IL) 18 treatment in murine tumor models, is promoted by
enhancing natural killer (NK)-mediated destruction of tumor and
delivery to dendritic cells (DCs). These activated and antigen-pulsed
DCs then critically and optimally induce an adoptive immune response,
positioning IL-18 as an important bridge between the innate and
adoptive immune response. The effect of IL-18 added to cultures of live
tumor cells (MCA205, a mouse sarcoma cell line), NK cells, DCs, and T
cells was assessed. When recombinant (r) mIL-18 protein was added to
this culture, potent NK cytolytic activity with subsequent generation
of CTLs was observed in a dose-dependent manner. Without introduction
of either rmIL-18 or NK cells into this culture, systemic cytolytic
activity was significantly decreased. Following the absence of direct
contact of either NK cells or DCs with other cells in this cooperative
coculture system using transwell, the systemic cytolytic activity of
both NK cells and CTLs was greatly suppressed. The cytolysis mediated
by effector cells harvested after completion of the culture was
primarily restricted to MHC class I and highly specific for the tumor
cells used in the coculture. Furthermore, we examined the efficiency in
the induction of cytolytic T cells of other established IFN-
inducing T-cell growth factors, IL-2, and IL-12 in this culture system
and compared them with that mediated by IL-18. Neither IL-2 nor IL-12
induced tumor-specific cytolytic T cells to the same degree as that
mediated by IL-18. Efficacy of this system in induction of
tumor-specific CTLs was also observed in the system using MC38
adenocarcinoma cells. These results are consistent with the notion that
IL-18 induces tumor-specific immunity through enhancing NK activity,
which in turn mediates tumor cell death and activates and primes DCs.
This article has been cited by other articles:
![]() |
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS J. Leukoc. Biol., July 1, 2008; 84(1): 1 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination J. Leukoc. Biol., July 1, 2008; 84(1): 27 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Robertson, J. W. Mier, T. Logan, M. Atkins, H. Koon, K. M. Koch, S. Kathman, L. N. Pandite, C. Oei, L. C. Kirby, et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4265 - 4273. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin. Cancer Res., May 1, 2006; 66(9): 4913 - 4921. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahmad and F. Alvarez Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis J. Leukoc. Biol., October 1, 2004; 76(4): 743 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ribas, J. A. Wargo, B. Comin-Anduix, S. Sanetti, L. Y. Schumacher, C. McLean, V. B. Dissette, J. A. Glaspy, W. H. McBride, L. H. Butterfield, et al. Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells J. Immunol., April 15, 2004; 172(8): 4762 - 4769. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Massa, C. Guiducci, I. Arioli, M. Parenza, M. P. Colombo, and C. Melani Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable hsp70 Cancer Res., February 15, 2004; 64(4): 1502 - 1508. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mashino, N. Sadanaga, F. Tanaka, M. Ohta, H. Yamaguchi, and M. Mori Effective Strategy of Dendritic Cell-based Immunotherapy for Advanced Tumor-bearing Hosts: the Critical Role of Th1-dominant Immunity Mol. Cancer Ther., August 1, 2002; 1(10): 785 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Veenstra, Z. L. Jonak, S. Trulli, and J. A. Gollob IL-12 Induces Monocyte IL-18 Binding Protein Expression Via IFN-{gamma} J. Immunol., March 1, 2002; 168(5): 2282 - 2287. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |